国际外科学杂志
國際外科學雜誌
국제외과학잡지
INTERNATIONAL JOURNAL OF SURGERY
2010年
1期
28-31,封3
,共5页
胡扬喜%杨星%乔安意%汤达承%王明俊
鬍颺喜%楊星%喬安意%湯達承%王明俊
호양희%양성%교안의%탕체승%왕명준
原发性肝癌%栓塞化疗%肝功能%疗效%回顾性分析
原髮性肝癌%栓塞化療%肝功能%療效%迴顧性分析
원발성간암%전새화료%간공능%료효%회고성분석
Hepatocellular carcinoma%Chemoembolization%Hepatic function%Hfficacy%Retrospective study
目的 探讨TACE治疗原发性肝癌的疗效及其对肝功能的影响.方法 HCC患者依治疗次数分为3组,以生存率和治疗前后肿瘤大小及AFP变化评估TACE疗效,通过比较肝功能相关指标(ALT、AST、ALB、DBLI、TBLI、PT)治疗前后的变化评估TACE治疗对肝功能的影响.结果 3个组的肿瘤缩小有效率分别为4.3%、23.1%、31.6%(P<0.05);组1和组2患者肝功能参数治疗前后差异无统计学意义(P>0.05),组3患者肝功参数皆出现不可逆性损害,和术前比较差异有统计学意义(P<0.05);3个治疗组1年、2年、3年生存率分别为27.0%、10.8%、5.4%,57.1%、33.3%、19.0%和62.5%、37.5%、18.8%,组2和组3的生存率比较差异无统计学意义(P<0.05).结论(1)3～4次TACE治疗可明显改善HCC患者长期生存率;(2)治疗引起的对肝功能的不可逆性损害可抵消TACE的部分疗效.
目的 探討TACE治療原髮性肝癌的療效及其對肝功能的影響.方法 HCC患者依治療次數分為3組,以生存率和治療前後腫瘤大小及AFP變化評估TACE療效,通過比較肝功能相關指標(ALT、AST、ALB、DBLI、TBLI、PT)治療前後的變化評估TACE治療對肝功能的影響.結果 3箇組的腫瘤縮小有效率分彆為4.3%、23.1%、31.6%(P<0.05);組1和組2患者肝功能參數治療前後差異無統計學意義(P>0.05),組3患者肝功參數皆齣現不可逆性損害,和術前比較差異有統計學意義(P<0.05);3箇治療組1年、2年、3年生存率分彆為27.0%、10.8%、5.4%,57.1%、33.3%、19.0%和62.5%、37.5%、18.8%,組2和組3的生存率比較差異無統計學意義(P<0.05).結論(1)3～4次TACE治療可明顯改善HCC患者長期生存率;(2)治療引起的對肝功能的不可逆性損害可牴消TACE的部分療效.
목적 탐토TACE치료원발성간암적료효급기대간공능적영향.방법 HCC환자의치료차수분위3조,이생존솔화치료전후종류대소급AFP변화평고TACE료효,통과비교간공능상관지표(ALT、AST、ALB、DBLI、TBLI、PT)치료전후적변화평고TACE치료대간공능적영향.결과 3개조적종류축소유효솔분별위4.3%、23.1%、31.6%(P<0.05);조1화조2환자간공능삼수치료전후차이무통계학의의(P>0.05),조3환자간공삼수개출현불가역성손해,화술전비교차이유통계학의의(P<0.05);3개치료조1년、2년、3년생존솔분별위27.0%、10.8%、5.4%,57.1%、33.3%、19.0%화62.5%、37.5%、18.8%,조2화조3적생존솔비교차이무통계학의의(P<0.05).결론(1)3～4차TACE치료가명현개선HCC환자장기생존솔;(2)치료인기적대간공능적불가역성손해가저소TACE적부분료효.
Objective To evaluate the therapeutic efficacy of transcather arterial chemoembolization for hepatic carcinoma and its influence on hepatic function. Methods Patients with HCC were divided into three groups according to repeated TACE times. The therapeutic efficacy was assessed with survival rate, car-cionma size and biologic response (AFP). Hepatic function was evaluated according to some hepatic param-eters(ALT,AST,ALB,DB,TB,PT). Results All three groups responses rates were 4.3%, 23.1% and 31.6% ;srespectively,liver function in group 1 and group 2 returned to its pretreatment level(P <0.05) ,but in group 3, liver function did not return to its pretreatment level associated with more repeated TACE times. The 1-,2-and 3-year survival rates of group 1 were 27.0%, 10.8%, 5.4% ; respectively, while those of group 2 were 57.1%, 33.3%, 19.0% ; respectively, which were not significantly different from those of Team 3 ,which was 62.5%, 37.5%, 18.8%, respectively. Conclusions (1) three to four repeated times TACE was an effective palliative treatment that prolongs survival of patients with HCC,while 1 to 2 re-peated times had a limited benefit; (2) Irreversible hepatic impairment induced by TAEC could affect its therapeutic efficacy.
